Association of phthalate exposure during early pregnancy with fetal growth and the effect modification by gestational

Nian Wu1, Zhongmei Hu2, Xinyi Xiao3

  • 1School of Public Health, Zunyi Medical University, No.6 Xuefu Xilu, Zunyi, 563006, China; Key Laboratory of Maternal and Child Health and Exposure Science , Guizhou Provincial Department of Education, China; Pingba District Center for Disease Control and Prevention, Anshun, 561100, China.

Insights

First-trimester exposure to phthalates (PAEs) is linked to impaired fetal growth. Pregnancy stress may worsen these effects, impacting fetal development.

Area of Science:

  • Environmental Health
  • Reproductive Toxicology
  • Prenatal Development

Background:

  • Phthalates (PAEs) are endocrine-disrupting chemicals with widespread exposure.
  • Prenatal exposure to environmental chemicals can impact fetal growth and development.
  • Pregnancy stress is a known factor influencing maternal and fetal health outcomes.

Purpose of the Study:

  • To investigate the association between first-trimester phthalates (PAEs) exposure and fetal growth parameters.
  • To explore whether first-trimester pregnancy stress modifies the relationship between PAEs exposure and fetal growth.

Main Methods:

  • A cohort of 704 pregnant women in their first trimester was analyzed.
  • Fetal growth parameters (e.g., HC, AC, FL, EFW, PT) were measured using ultrasonography.
  • Urinary concentrations of nine PAE metabolites were quantified; pregnancy stress was self-reported; statistical analyses included linear regression and Bayesian Kernel Machine Regression (BKMR).

Main Results:

  • Specific PAE metabolites (MEOHP, MBzP, MEP) were associated with reduced fetal growth metrics (HC, AC, FL).
  • Higher total PAE mixture concentrations were linked to lower femur length (FL) Z-scores.
  • Gestational stress was associated with reduced placental thickness (PT) and significantly modified PAE-fetal growth associations.

Conclusions:

  • First-trimester exposure to phthalates (PAEs) is associated with impaired fetal growth.
  • Gestational stress may amplify the adverse effects of PAEs on fetal development.
  • These findings highlight the importance of reducing PAE exposure during pregnancy, especially under stressful conditions.
Abstract

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Introduction to Stress and Lifestyle01:27

Introduction to Stress and Lifestyle

Stress is a multifaceted response to events perceived as challenging or threatening, highlighting physical, emotional, cognitive, and behavioral reactions. Physically, stress can lead to fatigue, sleep disruptions, and various health issues such as frequent colds, chest pains, and nausea. Emotionally, it can manifest as anxiety, depression, irritability, and anger triggered by both minor and major life events. Cognitively, it may result in difficulty in concentration, memory, and...